MREO Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Mereo Biopharma Group plc (MREO) following the 2026 Q2 hedge fund 13F filings?

As of today, MREO has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), MREO gained +0.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Mereo Biopharma Group plc (MREO)

61 + Investors. Track Smart Money conviction in MREO. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — MREO

Based on 62 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds reduced or closed their MREO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

📊

High ownership — 70% of 3.0Y peak

70% of all-time peak

62 funds currently hold this stock — 70% of the 3.0-year high of 89 funds (reached 2024 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.

📉

Outflows — 30% fewer funds vs a year ago

fund count last 6Q

26 fewer hedge funds hold MREO compared to a year ago (-30% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🟠

More sellers than buyers — 42% buying

29 buying40 selling

Last quarter: 40 funds reduced or exited vs 29 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 12 → 17 → 21 → 12. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

53% of holders stayed for 2+ years

■ 53% conviction (2yr+) ■ 19% medium ■ 27% new

33 out of 62 hedge funds have held MREO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💎

Buying through price weakness — shares +15%, value -9%

Value

-9%

+14%

Last quarter: funds added +15% more shares while total portfolio value only changed -9%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

13 → 12 → 17 → 21 → 12 new funds/Q

New funds entering each quarter: 12 → 17 → 21 → 12. A growing number of institutions are discovering MREO each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 63% veterans vs 30% newcomers

■ 63% veterans ■ 7% 1-2yr ■ 30% new

Entry-cohort mix of 67 holders: 42 (63%) are 2+ year veterans, 5 entered 1–2 years ago, and 20 (30%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 19% AUM from top-100

19% from top-100 AUM funds

13 of 61 holders rank in the top 100 by AUM, but together hold only 19% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

2.6

out of 10

Low Exit Risk

Exit risk score 2.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	61	72	-15.28%
13F Shares	77M	67M	14.63%
Total Value	$25M	$28M	-9.37%
New Positions	12	21	-9
Increased Positions	15	20	-5
Closed Positions	22	34	-12
Reduced Positions	18	19	-1
Total Calls	3	6	-50.0%
Total Puts	3	3	-
PUT/CALL Ratio	1.0	0.5	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

-15.28%

13F Shares

77M

67M

14.63%

Total Value

$25M

$28M

-9.37%

New Positions

-9

Increased Positions

-5

Closed Positions

-12

Reduced Positions

-1

Total Calls

-50.0%

Total Puts

PUT/CALL Ratio

1.0

0.5

Neutral

Institutional Holders (2026 Q2)

61 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MREO. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 MREO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Defilade Capital Management, L.P.	0.32%	7,558,756	$2.4M
2	Tejara Capital Ltd	0.27%	2,037,520	$647K
3	683 Capital Management, LLC	0.18%	11,777,856	$3.7M
4	Ishara Investments LP	0.18%	768,750	$244K
5	Newtyn Management, LLC	0.12%	3,000,000	$953K
6	Rangeley Capital, LLC	0.10%	329,200	$105K
7	Rubric Capital Management LP	0.04%	15,307,347	$4.9M
8	JMN Financial LLC	0.02%	76,748	$24K
9	EcoR1 Capital, LLC	0.02%	1,000,000	$318K
10	Significant Wealth Partners LLC	0.01%	32,677	$10K
11	James J. Burns & Company, LLC	0.00%	95,400	$30K
12	Quarry LP	0.00%	93,750	$30K
13	Wealthspire Advisors, LLC	0.00%	765,000	$243K
14	NFSG Corp	0.00%	18,750	$6K
15	XTX Topco Ltd	0.00%	174,481	$55K
16	Clear Harbor Asset Management, LLC	0.00%	32,000	$10K
17	Astoria Portfolio Advisors LLC.	0.00%	10,000	$3K
18	Two Sigma Securities, LLC	0.00%	12,900	$4K
19	Two Sigma Investments, LP	0.00%	1,319,241	$419K
20	Bank of America Corp /de/	0.00%	8,195,281	$2.6M
21	GAMMA Investing LLC	0.00%	9,308	$3K
22	Markowski Investments	0.00%	1,500	—
23	IHT Wealth Management, LLC	0.00%	15,000	$5K
24	Engineers Gate Manager LP	0.00%	23,953	$8K
25	Group One Trading LLC	0.00%	167,515	$53K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Mereo Biopharma Group plc (MREO)

What does the Smart Money Trend signal show for MREO?

Selling streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds reduced or closed their MREO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MREO?

More sellers than buyers — 42% buying: Last quarter: 40 funds reduced or exited vs 29 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for MREO holders?

Smaller funds dominant — 19% AUM from top-100: 13 of 61 holders rank in the top 100 by AUM, but together hold only 19% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MREO?

53% of holders stayed for 2+ years: 33 out of 62 hedge funds have held MREO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Mereo Biopharma Group plc (MREO) following the 2026 Q2 hedge fund 13F filings?

As of today, MREO has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), MREO has gained +0.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Mereo Biopharma Group plc (MREO)

Smart Money Signals — MREO

Selling streak — 2 quarters in a row

High ownership — 70% of 3.0Y peak

Outflows — 30% fewer funds vs a year ago

More sellers than buyers — 42% buying

Fewer new buyers each quarter (-9 vs last Q)

53% of holders stayed for 2+ years

Buying through price weakness — shares +15%, value -9%

Growing discovery — still being found

Veteran-anchored — 63% veterans vs 30% newcomers

Smaller funds dominant — 19% AUM from top-100

Institutional Sentiment Summary — MREO

Hedge Fund Ownership: MREO

Market Analysis: MREO

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: MREO

Is It Too Late to Buy Mereo Biopharma Group plc (MREO) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: MREO

Statistics: MREO

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Mereo Biopharma Group plc (MREO)

Welcome to 13Foresight!